Lamictal 50mg 28 dispersible tablets — Made in Poland — Free Delivery

Product description

Lamictal tablets are used for the following indications:

Epilepsy:

• adults and children over the age of 13:
• adjunctive therapy or monotherapy for partial and generalized seizures of epilepsy, including tonic-clonic seizures;
• seizures associated with Lennox-Gastaut syndrome (Lamictal is prescribed as an adjunct therapy, but in Lennox-Gastaut syndrome, it can be prescribed as an initial antiepileptic preparation (PEP));
• children aged 2 to 12 years:
• adjunctive therapy for partial and generalized seizures of epilepsy, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome;
• monotherapy for typical absences.
• Bipolar Disorder (Adults 18+): Prevention of depressive conditions in patients with bipolar I disorder who are predominantly depressed (Lamictal is not indicated for the emergency treatment of manic or depressive episodes).

Compound

Active substance: lamotrigine;

1 tablet contains lamotrigine 25 mg or 50 mg, 100 mg;

Excipients: lactose, microcrystalline cellulose, povidone K30, sodium starch (type A), iron oxide yellow (E172), magnesium stearate.

Contraindications

Lamictal is contraindicated in patients with known hypersensitivity to lamotrigine or to any other component of the preparation.

Mode of application

Lamictal tablets should be swallowed whole without chewing or breaking.

If the estimated dose of lamotrigine (for example, for the treatment of children with epilepsy or patients with impaired liver function) is not a multiple of the whole tablets, the dose that is applied should correspond to the nearest smaller number of whole tablets.

Application features

Pregnant

If therapy with Lamictal is considered necessary during pregnancy, it is recommended to use it in the lowest possible therapeutic dose.

Children

This preparation is not recommended for use in children with bipolar disorder (under 18 years of age) because randomized withdrawal trials have not shown significant efficacy and have shown an increase in suicidality rates.

Drivers

Since there is an individual reaction to antiepileptic preparations, the patient should consult a doctor about the peculiarities of driving in these cases.

Overdose

There are reports of cases of acute overdose (when taking doses that are 10-20 times higher than the maximum therapeutic dose), including deaths. Overdose symptoms were ataxia, nystagmus, impaired consciousness, major seizures, and coma. Also, in case of an overdose, it was reported about the expansion of the QRS complex (delayed intraventricular conduction). Expansion of the QRS complex to more than 100 msec may be associated with more severe toxicity.

In case of overdose, the patient must be hospitalized for appropriate supportive therapy. It is necessary to apply therapy aimed at reducing absorption (activated carbon), if necessary. Additional treatment is prescribed according to clinical indications. There is no experience in the use of hemodialysis for the treatment of overdose. In six volunteers with renal insufficiency, 20% of lamotrigine was excreted during a 4-hour hemodialysis session.

Side effects

Psychiatric disorders: very often (≥ 1/10) - aggression, irritability.

From the nervous system: very often (≥ 1/10) - headache; often (≥ 1/100, <1/10) - drowsiness, dizziness, tremors, insomnia, anxiety.

From the gastrointestinal tract: often (≥ 1/100, <1/10) - nausea, vomiting, diarrhea, dry mouth.

On the part of the skin and subcutaneous tissue: very often (≥ 1/10) - skin rash.

On the part of skeletal muscles and connective tissue: often (≥ 1/100, <1/10) - arthralgia.

Interaction

Interaction studies were conducted only in adults.

In a study of 10 male volunteers who took rifampicin, the elimination rate and half-life of lamotrigine increased and the half-life of lamotrigine decreased due to the induction of hepatic enzymes responsible for glucuronidation. In patients receiving concomitant rifampicin therapy, the treatment regimen recommended for treatment with lamotrigine and appropriate glucuronidation inducers should be used.

According to studies conducted on healthy volunteers, lopinavir / ritonavir approximately halved the plasma concentration of lamotrigine by inducing glucuronidation. For the treatment of patients who are already using lopinavir / ritonavir, you should adhere to the therapy regimen recommended for the use of lamotrigine and glucuronidation inducers.

Storage conditions

Store at temperatures below 30 ° C.

Keep out of the reach of children.

Shelf life is 3 years.